导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.31% | 2121/4773 |
| 近一周 | -1.85% | 794/5462 |
| 近一月 | -2.61% | 1344/5421 |
| 近一季 | -8.64% | 2890/5209 |
| 近半年 | -3.57% | 2250/4920 |
| 近一年 | 4.72% | 1676/4366 |
| 近两年 | 60.50% | 1200/2954 |
| 近三年 | 42.44% | 666/2253 |
| 成立以来 | 104.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.03% 1672/4961 |
10.18% 2437/5312 |
- - |
- - |
| 2025 | 26.26% 1641/4813 |
2.31% 1408/3635 |
5.85% 533/4076 |
13.42% 3000/4524 |
2.80% 845/4813 |
| 2024 | 20.77% 440/3463 |
2.25% 803/2808 |
0.67% 559/3014 |
15.22% 1783/3129 |
1.83% 1023/3463 |
| 2023 | -9.52% 1183/2656 |
2.92% 1287/2280 |
-2.71% 636/2385 |
-3.39% 913/2515 |
-6.47% 1791/2655 |
| 2022 | -21.19% 1014/2207 |
-14.76% 995/1919 |
6.22% 748/2016 |
-13.44% 906/2113 |
0.56% 1485/2208 |
| 2021 | -2.53% 858/1822 |
-2.88% 720/1255 |
5.51% 806/1330 |
-4.55% 718/1466 |
-0.35% 1227/1822 |
| 2020 | 50.01% 171/1250 |
-6.80% 511/1028 |
17.22% 383/1067 |
17.10% 118/1164 |
17.26% 133/1184 |
| 2019 | 43.52% 190/1092 |
26.62% 390/739 |
1.54% 121/788 |
1.45% 399/850 |
10.03% 170/918 |
| 2018 | -19.44% 164/834 |
- - |
-7.43% 161/631 |
-0.06% 167/660 |
-11.85% 367/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 安信量化精选沪深300增强C VS. 长安沪深300非周期A(740101) |